Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Kiniksa Pharmaceuticals Ltd (KNSA) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 297 employees
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Total Value
-$11,785,115.88
Total Shares
-921
Average Trade Value
-$153,053.45
Most Active Insider
Patel Sanj K
Total Activity: $6,228,680
Largest Single Transaction
$2,059,903
by Patel Sanj K on Nov 6, 2024
30-Day Activity
16 Transactions
Volume: 13,563 shares
Value: $1,062,256
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Operating Officer
|
Dec 16, 2024 | 23,017 | $470,467 | 95,975 (-24.0%) | Sale | |
|
Chief Operating Officer
|
Dec 16, 2024 | 16,017 | $25,467 | 118,992 (+13.5%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 9, 2024 | 18,860 | $403,227 | 22,958 (-82.2%) | Sale | |
|
Chief Financial Officer
|
Dec 9, 2024 | 18,860 | $209,346 | 41,818 (+45.1%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 6, 2024 | 2,406 | $25,889 | 25,364 (+9.5%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 6, 2024 | 8,969 | $190,771 | 22,958 (-39.1%) | Sale | |
|
Chief Financial Officer
|
Dec 5, 2024 | 1,123 | $12,083 | 24,081 (+4.7%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 5, 2024 | 1,123 | $23,864 | 22,958 (-4.9%) | Sale | |
|
Chief Financial Officer
|
Dec 4, 2024 | 5,024 | $106,760 | 22,958 (-21.9%) | Sale | |
|
Chief Financial Officer
|
Dec 4, 2024 | 5,024 | $54,058 | 27,982 (+18.0%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 3, 2024 | 8,969 | $192,385 | 22,958 (-39.1%) | Sale | |
|
Chief Financial Officer
|
Dec 3, 2024 | 8,969 | $96,506 | 31,927 (+28.1%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Nov 29, 2024 | 9 | $100 | 26,537 (+0.0%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Nov 29, 2024 | 9 | $202 | 26,528 (-0.0%) | Sale | |
|
Chief Accounting Officer
|
Nov 27, 2024 | 8,637 | $193,901 | 26,528 (-32.6%) | Sale | |
|
Chief Accounting Officer
|
Nov 27, 2024 | 8,637 | $95,871 | 35,165 (+24.6%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Nov 18, 2024 | 17,000 | $357,680 | 102,975 (-16.5%) | Sale | |
|
Chief Operating Officer
|
Nov 18, 2024 | 10,000 | $15,900 | 119,975 (+8.3%) | Exercise/Conversion | |
| Nov 7, 2024 | 1,303 | $10,000 | 14,200 (+9.2%) | Exercise/Conversion | ||
|
Chairman CEO
|
Nov 6, 2024 | 89,561 | $142,402 | 169,112 (+53.0%) | Exercise/Conversion | |
|
Chairman CEO
|
Nov 6, 2024 | 89,561 | $2,059,903 | 79,551 (-112.6%) | Sale | |
|
Chief Operating Officer
|
Oct 15, 2024 | 17,000 | $456,790 | 109,975 (-15.5%) | Sale | |
|
Chief Operating Officer
|
Oct 15, 2024 | 10,000 | $15,900 | 126,975 (+7.9%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Oct 4, 2024 | 175 | $10,000 | 26,610 (+0.7%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Oct 4, 2024 | 82 | $2,007 | 26,528 (-0.3%) | Payment of Exercise Price | |
| Oct 4, 2024 | 4,730 | $0 | 128,802 (+3.7%) | Grant | ||
| Oct 4, 2024 | 4,730 | $0 | 2,730,419 (+0.2%) | Grant | ||
|
Chief Operating Officer
|
Sep 23, 2024 | 17,500 | $437,325 | 116,975 (-15.0%) | Sale | |
|
Chief Operating Officer
|
Sep 23, 2024 | 10,000 | $15,900 | 134,475 (+7.4%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 3, 2024 | 29,730 | $330,003 | 65,466 (+45.4%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 3, 2024 | 24,776 | $296,569 | 90,242 (+27.5%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 3, 2024 | 67,346 | $1,757,731 | 22,896 (-294.1%) | Sale | |
|
Chief Commercial Officer
|
Sep 3, 2024 | 14,000 | $123,620 | 35,736 (+39.2%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 3, 2024 | 1,160 | $31,459 | 21,736 (-5.3%) | Sale | |
|
Chief Medical Officer
|
Sep 3, 2024 | 60,217 | $112,004 | 112,255 (+53.6%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Sep 3, 2024 | 59,214 | $1,544,893 | 53,516 (-110.6%) | Sale | |
|
Chief Medical Officer
|
Sep 3, 2024 | 1,478 | $40,098 | 52,038 (-2.8%) | Sale | |
|
Chief Medical Officer
|
Sep 3, 2024 | 475 | $1,805 | 112,730 (+0.4%) | Exercise/Conversion | |
|
Chairman CEO
|
Sep 2, 2024 | 3,177 | $84,953 | 79,551 (-4.0%) | Payment of Exercise Price | |
|
Chief Commercial Officer
|
Sep 2, 2024 | 994 | $10,000 | 22,081 (+4.5%) | Exercise/Conversion | |
|
Chairman CEO
|
Sep 2, 2024 | 6,569 | $10,000 | 82,728 (+7.9%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Sep 2, 2024 | 1,964 | $10,000 | 125,052 (+1.6%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Sep 2, 2024 | 775 | $10,000 | 26,764 (+2.9%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Sep 2, 2024 | 329 | $8,797 | 26,435 (-1.2%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Sep 2, 2024 | 1,725 | $10,000 | 52,873 (+3.3%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Sep 2, 2024 | 835 | $22,328 | 52,038 (-1.6%) | Payment of Exercise Price | |
|
Chief Commercial Officer
|
Sep 2, 2024 | 345 | $9,225 | 21,736 (-1.6%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Sep 2, 2024 | 956 | $25,563 | 22,958 (-4.2%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Sep 2, 2024 | 1,861 | $10,000 | 23,914 (+7.8%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Sep 2, 2024 | 577 | $15,429 | 124,475 (-0.5%) | Payment of Exercise Price | |
|
Chairman CEO
|
Sep 1, 2024 | 16,474 | $10,000 | 84,126 (+19.6%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Sep 1, 2024 | 6,490 | $10,000 | 28,744 (+22.6%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 1, 2024 | 1,393 | $37,249 | 21,087 (-6.6%) | Payment of Exercise Price | |
|
Chairman CEO
|
Sep 1, 2024 | 7,967 | $213,038 | 76,159 (-10.5%) | Payment of Exercise Price | |
|
Chief Commercial Officer
|
Sep 1, 2024 | 4,089 | $10,000 | 22,480 (+18.2%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Sep 1, 2024 | 4,444 | $10,000 | 24,313 (+18.3%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Sep 1, 2024 | 2,260 | $60,432 | 22,053 (-10.2%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Sep 1, 2024 | 1,994 | $53,320 | 51,148 (-3.9%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Sep 1, 2024 | 2,755 | $73,669 | 25,989 (-10.6%) | Payment of Exercise Price | |
|
Chief Operating Officer
|
Sep 1, 2024 | 4,499 | $10,000 | 124,410 (+3.6%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Sep 1, 2024 | 4,121 | $10,000 | 53,142 (+7.8%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Sep 1, 2024 | 1,322 | $35,350 | 123,088 (-1.1%) | Payment of Exercise Price | |
|
Chief Operating Officer
|
Aug 27, 2024 | 10,000 | $15,900 | 137,411 (+7.3%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Aug 27, 2024 | 17,500 | $470,925 | 119,911 (-14.6%) | Sale | |
|
Chief Financial Officer
|
Jul 23, 2024 | 24,248 | $269,153 | 43,501 (+55.7%) | Exercise/Conversion | |
|
Chairman CEO
|
Jul 23, 2024 | 136,124 | $216,437 | 199,136 (+68.4%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Jul 23, 2024 | 100 | $2,787 | 47,803 (-0.2%) | Sale | |
|
Chief Medical Officer
|
Jul 23, 2024 | 8,446 | $228,887 | 47,903 (-17.6%) | Sale | |
|
Chief Medical Officer
|
Jul 23, 2024 | 22,000 | $40,920 | 69,803 (+31.5%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Jul 23, 2024 | 7,924 | $208,877 | 56,349 (-14.1%) | Sale | |
|
Chairman CEO
|
Jul 23, 2024 | 23,075 | $536,494 | 176,061 (-13.1%) | Sale | |
|
Chief Medical Officer
|
Jul 23, 2024 | 5,530 | $138,416 | 64,273 (-8.6%) | Sale | |
|
Chairman CEO
|
Jul 23, 2024 | 63,049 | $1,702,953 | 63,012 (-100.1%) | Sale | |
|
Chief Financial Officer
|
Jul 23, 2024 | 24,248 | $601,108 | 19,253 (-125.9%) | Sale | |
|
Chairman CEO
|
Jul 23, 2024 | 50,000 | $1,252,500 | 126,061 (-39.7%) | Sale | |
|
Chief Commercial Officer
|
Jul 15, 2024 | 211 | $3,302 | 18,391 (+1.1%) | Grant | |
|
Chief Accounting Officer
|
Jul 15, 2024 | 480 | $7,512 | 22,254 (+2.2%) | Grant |